GEV vs MRK: Which Is the Better Buy?

Side-by-side comparison of GE Vernova Inc. and Merck & Co., Inc. โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-24.
GE Vernova Inc. ยท Industrials
$951.82
+35.4% upside to fair value
Med Conviction Grade B High Quality
VS
Merck & Co., Inc. ยท Healthcare
$147.17
-4.1% upside to fair value
Med Conviction Grade C
QuantHub Verdict
GEV has more upside to fair value (+35.4%). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric GEV MRK
Current Price $951.82 $147.17
Fair Value Estimate $1,288.67 $141.07
Upside to Fair Value +35.4% -4.1%
Market Cap $253.5B $363.5B
Forward P/E โ€” โ€”
EV / EBITDA 28.2x 29.6x
Price / Sales 6.1x 5.5x
Price / FCF 20.5x 22.6x
Revenue Growth YoY +21.9% +5.1%
Gross Margin 20.2% 75.4%
Operating Margin 4.4% 16.7%
Return on Equity 83.4% 6.6%
Dividend Yield 0.18% 2.31%
FCF Yield 4.88% 4.42%
Analyst Consensus Strong Buy Buy
Investment Thesis
GEV โ€” GE Vernova Inc.
GE Vernova is an energy equipment and infrastructure enterprise spanning Power (gas, nuclear, hydro, steam), Wind (offshore and onshore turbines), and Electrification (grid, power conversion, solar and storage), with 78,000 employees and a Cambridge, Massachusetts headquarters. The business quality is high on the strength of an installed base that generates roughly 25% of the world's electricity,โ€ฆ
MRK โ€” Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely higโ€ฆ
Accumulation Zones
Metric GEV MRK
Zone Low $966.50 $105.80
Zone High $1,095.37 $119.91
In Buy Zone? Yes No
โ† GEV Research    MRK Research โ†’    All Research